Dong et al. [61] showed that when used in combination with gene therapy, IGF-1 therapy promotes skeletal muscle hypertrophy and improved contractile function in mice suffering from peripheral arterial disease, while Lynch et al. [62] demonstrated that IGF-1 treatment increases force-producing capabilities and skeletal muscle mass in dystrophic mice. Here, IGF1 is linked to peripheral arterial disease.